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Previous work  from  this  laboratory  (1,  2)  has  characterized  the  phenomenon  of 
effector-cell blockade (ECB), 1 in which  interaction of an antibody-forming cell with 
specific antigen  results  in  inhibition  of antibody secretion.  Other examples of ECB 
have been reported by Baker et al.  (3) and by Klaus and Humphrey (4). 
Multivalency  of the  antigen,  that  is,  high  hapten:carrier  ratio  was  found  to  be 
critical (1, 2, 5, 6). Furthermore, the removal of cell-bound antigen resulted in reversal 
of the blockade  (2), suggesting that  inhibition  of antibody secretion  is  mediated  by 
persistence of antigen on the cell membrane. Thus, ECB is of interest  not only as an 
example of immune regulation but also as a  potential example of membrane-immu- 
noglobulin-mediated transmission of regulatory signals. 
The particular advantage of ECB as a  model for the study of at least one type of 
Ig-receptor-mediated signaling  is  that  the  effects of antigen  binding  are  detectable 
after only 20 min. Furthermore, changes can be studied at the level of the single cell, 
where  other  cell-cell  interactions  are  absent  (1),  and  involve  the  major  secretory 
product of the cell, specific antibody. ECB is detectable not only in normal antibody- 
forming cells; but also in their neoplastic counterparts, myeloma cells (7-10). 
Cloned cell lines such as myelomas offer significant  advantages in elucidating the 
molecular mechanisms underlying  this  phenomenon  because they can  be grown  in 
quantity as a relatively homogeneous population by standard tissue culture methods. 
Abbas and  Klaus  (7,  8)  and  Abbas  (10)  have used the  IgA-secreting, dinitrophenol 
(DNP)-binding myeloma MOPC  315  to show  that  secretion  of IgA is  inhibited  by 
suitable  DNP-conjugated  proteins or by antigen-antibody  complexes. In our study, 
we describe the  production  and  characterization  of a  hybridoma cell  line  that  was 
designed  to  facilitate  a  parallel  study  of the  biochemical  and  membrane-receptor 
changes occurring in ECB. 
1Abbreviations used in  this paper: AFC, antibody-forming cells; BSA, bovine serum albumin; DME, 
Dulbecco's modified Eagle's medium; DNP, dinitrophenol; ECB, effector-cel[  blockade; FACS, fluores- 
cence-activated  cell sorter; FCS, fetal calf serum; FITC, fluorescein isothiocyanale;  FLU, fluorescein-(ated); 
FluIgM-1, ascites fluid from tumors that contained IgM; GEL, gelatin; HAT, hypoxanthine-aminopterin- 
thioguanine;  HGG, human  gamma globulin;  HT  medium, hypoxanthioe-thioguanine-supplemented 
DME; NET buffer, 150 raM/liter NaCI, 5 raM/liter EDTA, 50 raM/liter Tris, and 0.2% sodium azide (wt: 
vol); NIP, mononitroiodophenyl; NP40, Nonidet P-40; PBS, phosphate-buffered saline; PFC, plaque- 
forming cells; POL, polymerized  flagellin; PVC, polyvinyl  chloride; RIA, solid-phase radioimmunoassay; 
SRBC, sheep erythrocytes;  TCA, trichloroacetic acid. 
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The cell line we describe secretes IgM antibody specific for the hapten  fluorescein 
(FLU)  that  through  its  fluorescence  properties  offers  a  simple  means  of directly 
monitoring  the  fate  of antigen  bound  to  the  cell  surface.  We  document  here  the 
susceptibility of the cell line to ECB, as measured both by the inhibition of hemolytic 
plaque formation and by the specific reduction of Ig secretion and synthesis. Parallel 
observations on the fate of cell-bound antigen are described. 
Materials  and  Methods 
Antigens.  FLU conjugates were  prepared  by coupling fluorescein isothiocyanate (FITC; 
Molecular Probes, Rockville, Minn.) to proteins in bicarbonate buffer (pH 9) (11). The reagent 
most  extensively used  in  this  study  was  FLUzo gelatin  (GEL)  (FLU20GEL),  prepared  by 
coupling 20 mg of FITC per 100 mg of gelatin (Parke, Davis & Co., Sydney, Australia). This 
yielded a conjugate having 20 FLU groups/105 daltons of gelatin. 
FLU-bovine serum albumin (BSA)  (FLU10  BSA) was prepared in a  similar manner using 
crystalline BSA (Armour Pharmaceutical Co., Eastbourne, England). The other FLU conju- 
gates, generously supplied by B. L. Pike, Walter and Eliza Hall Institute of Medical Research, 
Royal Melbourne Hospital, Victoria, Australia, were prepared in the same fashion. 
Animals.  BALB/c mice were used as the source of normal antibody-forming cells in  the 
hybridoma fusions. Subsequently, cloned hybridoma lines were injected intraperitoneally (107 
cells/mouse) to establish ascitic tumors. The tumor was passaged in these mice, and resultant 
ascites fluid that contained hybridoma IgM (FlulgM-1), was harvested for use in immunopre- 
cipitation assays described. 
Tissue Culture Conditions.  Cells were cultured in Dulbecco's modified Eagle's medium (DME) 
with 10% fetal calf serum (FCS) in a  10% CO2 incubator. Both hybridoma cells and NS-1 (the 
parent myeloma line) were cultured under identical conditions. Cells were harvested late in the 
log phase of growth at a density of ~5 X  105/ml, at which stage viability was high (>8.5%). 
Hybridoma Production.  BALB/c mice were  immunized  intraperitoneally with  10/tg/ml  of 
FLU-conjugated, polymerized flagellin (POL)  (FLU-POL) 3 d before fusion. Previous experi- 
ence with hemolytic plaque assays showed that IgM-secreting antibody-forming cells were most 
numerous at this stage. These mice were killed by cervical dislocation and the spleens removed. 
Spleen cells were carefully teased out with forceps, yielding a high viability (>90% after washing 
in fresh medium) population of spleen cells in serum-free DME. Fusion of 1.4 ×  l0  s spleen cells 
and 1.4 X  10  7 hypoxanthine-aminopterin-thioguanine (HAT)-sensitive, nonsecreting myeloma 
cells (NS-1) was performed, using the technique of KiShler and Milstein (12). 
The fusion products were then incubated in DME-15% FCS for 24 h before aliquoting into 
two 24-well Linbro trays (No. 76-033-0.5; Linbro Chemical Co., Hamden, Conn.) with 2 ×  10  s 
cells per well, and 64 of the 96 wells of a  Linbro No.  76-013-0.5 tray with 5 ×  105 cells/well, 
which contained 1 ml and 0.2 ml of HAT medium, respectively. 
The wells were fed every 48 h for 2 wk with HAT medium. At the end of this period feeding 
was continued with hypoxanthine-thioguanine-supplemented DME  (HT medium), and wells 
were examined for growth. Supernates were removed from wells showing proliferation and were 
tested  for the presence of Ig by solid-phase radioimmunoassay (RIA) on  FLU10BSA-coated 
plates (see below), and by hemolytic plaque testing. The cells in wells that contained the most 
antibody were cloned by limiting-dilution with 10% positive wells used as the end point. 
Antisera.  Rabbit anti-FlulgM-  1 was obtained by immunizing rabbits with 500/~g of purified 
hybridoma protein in complete Freund's adjuvant every 4  wk. The hybridoma protein was 
purified by dialysis against double-distilled water to obtain precipitated FlulgM-1 which was 
then dissolved in phosphate-buffered saline (PBS). Affinity chromatography was then carried 
out, using FLUz0GEL-coupled Sepharose 4B (Pharmacia Fine Chemicals, Div. of Pharmacia, 
Inc., Piscataway, N. J.). The eluted protein was judged to be pure in that the only bands that 
were visualized on sodium dodecyl sulfate-polyacrylamide gels stained with Coomassie Blue 
corresponded to the heavy and light chains of IgM. 
Normal rabbit serum used in the precipitation experiments was absorbed by three passages 
over a column of Sepharose 4B coupled with normal mouse Ig, followed by two passages over 
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Another rabbit antiserum (R647)  with strong anti-# chain activity, raised against purified, 
polyspecifie IgM, was.obtained from J. E. Layton (Walter and Eliza Hall Institute of Medical 
Research,  Royal Melbourne Hospital, Victoria, Australia). 
Biosynthetic  Labeling  Protocol.  Hybridoma cells, at a  density of 2.5  ×  106/ml,  were treated 
with blockading antigen for 1 h at 37°C in DME-10% FCS. Controls were incubated in parallel 
in the absence of antigen. The cells were then diluted with 10 ml of ice-cold DME and washed 
by centrifuging  at 600 g for I0 min through an FCS underlayer. This process was then repeated. 
(It  was  found that  further washing made no difference to the results.)  The pellet was  then 
resuspended in 1 ml of the biosynthetic labeling medium. This consisted of DME containing 
only 10  -s M  leucine, 10%  FCS, and 20 #Ci/ml of L-[6-aH]leucine  (Amersham, Eastbourne, 
England). Incubation was performed in Falcon (No.  2058;  Falcon Labware, Div. of Becton, 
Dickinson & Co., Oxnard, Calif.) test tubes for 4 h. Comparison with incubation in 2-ml Petri 
dishes showed  little difference in results,  but recovery of cells was facilitated by the use of the 
test tubes. 
After incubation, the cell suspension was centrifuged at 600 g for  10 min through an FCS 
underlayer. Supernates were removed and placed in test  tubes. In most instances, FLU20GEL 
was  the  antigen employed;  10 #g/ml  of collagenase (A  grade;  Calbiochem-Behring Corp., 
American Hoechst Corp., San Diego,  Calif.)  was added where it was desirable to digest any 
FLU~0GEL that was  present. The nonionic detergent Nonidet P-40 (NP40)  (Shell  Chemical 
Co.,  New York)  was  then added to a  final concentration of 0.5% vol/vol, to the supernates, 
which were stored at -20°C. The cell pellet was lysed  in 0.5% NP40 in buffer 150 raM/liter 
NaCI,  5 raM/liter EDTA, 50  mM/liter Tris, and 0.2% (wt:vol)  sodium azide buffer (NET 
buffer) plus 10 #g/ml collagenase if residual FLU20GEL was to be digested, and then centrifuged 
at 2,000 g for  10 rain to remove debris. The supernates were removed and stored at -20°C. 
Plaque-forming  Cell (PFC)  Assay.  FLU-specific IgM antibody secretion was  detected using 
the Cunningham and Szenberg (13) modification of the Jerne hemolytic plaque assay with 
sheep erythrocytes (SRBC) coated with FLU-conjugated F(ab')2 fragments of rabbit anti-SRBC 
(FLU-SRBC). The hybridoma cells  (50 #l)  were  mixed with 50 #1 of 2% vol/vol FLU-SRBC 
and a  1:20 dilution of guinea pig serum as a source of complement. The mixture was pipetted 
into Cunningham chambers which were sealed with paraffin. After 1 h at 37°C the chambers 
were examined with a colony microscope at magnification of 25, and the number and size of 
plaques were determined. 
Trichloroacetic Acid  (TCA)  Precipitation.  The samples (10 #l)  were mixed with 50 #[ of 20% 
FCS in serology  tubes, and protein precipitated with  1 ml of ice-cold  20% TCA, which was 
vortexed and then diluted with 4 ml of 5% TCA. The tubes were then centrifuged at 2,000 g for 
10 minutes, and the supernate removed. The pellet was dissolved in a small volume of 0.4 N 
NaOH, reprecipitated as above, centrifuged, and the pellet dissolved  in 100 #1 of 0.4 N NaOH. 
This material was  then placed  in scintillation vials,  solubilized with  300 #1  of Soluene-350 
(Packard  Instrument Co.,  Inc., Downers Grove, Ill.),  and 4  ml of scintillation fluid added, 
Samples were counted on a Packard Scintillation  Counter (Packard Instrument Co., Inc.). 
Direct  Coprecipitation.  Direct  coprecipitation was  carried  out  by adding 25 #1  of pooled 
FluIgM-  1 ascites to 25 #1 of the sample, diluting the mix in 200 #1 of 0.5% NP40-PBS, vortexing, 
then adding a previously optimized amount of FLU-BSA to yield a maximal precipitate. The 
precipitates were incubated at 37°C for  1 h, then at 4°C overnight. Precipitates were washed 
three times in 0.5% NP40-PBS, then dissolved  in 100 #1 of 0.1  M acetic acid and prepared for 
counting as for TCA precipitates. 
Indirect  Coprecipitation  Using Staphylococci.  The method of Kessler (14), was used to measure 
IgM.  Briefly,  50 #1 of sample, 200 #1 of 0.5% NP40-NET buffer and  10 #l of specific  anti-# 
antiserum were incubated for  1 h at 37°C. After this time, 200 #l of a  10% suspension of heat- 
killed,  formalin-treated Cowan I  strain Staphylococcus  aureus  (in 0.5% NP40-NET buffer)  was 
added and incubation continued for a  further  15 min. The preparations were washed three 
times in 0.5% NP40-NET. The final pellet then mixed with 100 #1 of 0.1 M acetic acid to elute 
bound IgM and centrifuged at 2,000 g for  10 rain. Supernates were removed and counted as 
before. 
The Measurement  of Biosynthetically  Labeled Antibody  by a Solid-Phase Immunoabsorbent.  Polyvinyl 
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Virginia) were treated with FLU-BSA (10 -4 M  fluorescein) for 24 h at room temperature. Any 
remaining binding sites on the plastic were then blocked with 10% agammaglobulinemic horse 
serum. Plates were dried and stored at 4°(2 until they were used. 
An aliquot, (50/~l)  of each sample of the biosynthetically labeled supernates or cell lysates, 
was added to a designated well and the plate was incubated at 4°(2 overnight. The plates were 
then washed 10 times, cut up with scissors and individual wells transferred to scintillation vials, 
to which was added 5 ml of 25% Triton X-100 in scintillation fluid and which were counted as 
before. 
Solid-phase Radioimmunoassay. The method of Teale et al. (15) was employed. Samples (50/.d) 
were added to wells of FLUl0BSA-coated PV(2 plates as above. After overnight incubation, the 
plates were washed twice, and aliquots of 12sI-iabeled antiserum provided by Dr. J. Teale (The 
Walter and Eliza Hall Institute of Medical Research), either directed against Fab fragments or 
against class-specific determinants, were added. The plates were incubated for 24 h, washed l0 
times and cut up, individual wells being placed in tubes for counting on a Beckman Autogamma 
counter (Beckman Instruments, Inc., Electronic Instruments Div., Schiller Park, Ill.). 
Thymidine Uptake.  1/~(2i  [aH]thymidine (Amersham) was added to  1 ml of cell suspension. 
The  cells were  harvested on  glass fiber filters and  washed  extensively with  distilled water. 
Radioactivity was measured by transferring the dried filters to scintillation vials, solubilizing 
with 300/~1 of Soluene-350 and adding 4.5 ml of scintillation fluid. 
Fluorescence Microscopy.  Cells were directly labeled with rhodamine-conjugated sheep anti- 
mouse  Ig  (prepared by J.  E.  Layton), or with  the  blockading fluorescein conjugates  (e.g., 
FLU20GEL). The cells were incubated for various times at 4°C or 37°(2  before preparation for 
examination by either fluorescence microscopy or the fluorescence-activated cell sorter (FACS) 
(Beeton, Dickinson FA(2S Systems, Mountain View, Calif.) (16,  17). In other experiments, cells 
were  incubated  with  the  rabbit  anti-FluIgM-1  antiserum  for  varying times,  washed,  then 
stained with rhodamine-eonjugated sheep anti-rabbit antiserum for  10 min at 4°C. The cells 
were then washed and studied by fluorescence microscopy. 
In some experiments the cells were washed twice and examined immediately, whereas in 
other  experiments,  washed  cells  were  fixed  in  paraformaldehyde  and  stored  at  4°C.  No 
difference was detected in the fluorescence associated with cells treated by these two methods. 
Fc Receptor Rosettes.  Washed SRB(2 were incubated at 37°C with rabbit anti-SRBC antise- 
rum (obtained from B. L. Pike) for 30 min, then washed, and reconstituted to a 5% suspension 
in normal saline. The rosetting assay was carried out by mixing equal volumes of the SRBC 
suspension with hybridoma cells or peritoneal exudate cells. The mixtures were incubated at 
37°(2 for 40 min, then examined for rosettes in a hemocytometer. 
In experiments investigating the presence of Fc receptors capable of binding IgM, sheep 
erythrocytes were  coated  with  IgM  antibody  using  serum  obtained  from  mice  4  d  after 
immunizing with sheep erythrocytes, when the bulk of anti-SRBC antibodies are of the IgM 
class. 
Statistical Calculations.  The Student's t test was used to determine significance. In general, 
tests were performed three or four times and means and standard errors are presented. 
Results 
Anti-Fluorescein-Antibody-secreting  Hybridoma.  Tissue  cultures  were  examined  for 
growth  14  d  after  the  fusion  of NS-1  myeloma  cells  with  spleen  cells  from  mice 
injected 3  d  previously with FLU-POL.  Proliferating cells were observed in 25 wells 
of the 96-well tray and in all wells of the 24-well trays. Supernates from these wells 
were  tested  for  the  presence  of anti-FLU  antibodies  using  the  radioimmunoassay 
based on FLU-BSA-coated plates. Antibody was detected in 9  of the 25 small wells, 
and in most wells of the 24-well trays. Supernates were also tested for the presence of 
various Ig classes using isotype-specific radioiodinated antisera (Fig.  1). This demon- 
strated that  in  all but  one well, the secreted immunoglobulin was IgM;  in well  19, 
IgG2a was detected. 
Aliquots of cells from  each  well were  frozen  in  liquid  nitrogen.  The  eight  wells 1440  EFFECTOR-CELL  BLOCKADE  IN  A  FLUORESCEIN-SPECIFIC  HYBRIDOMA 
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Fro.  l.  Measurement of antibody production in wells 2 wk after a hybridoma fusion. The counts 
per  minute of l~SI-labeled  anti-kappa  antiserum used  in  the  RIA  are  plotted  for  each well  that 
showed growth 2 wk after fusion of spleen cells from mice immunized with FLU-POL with the NS- 
1 myeloma line. 
showing highest  levels  of anti-FLU  antibody production  were  cloned  by  limiting 
dilution two times (Fig.  i, wells 3,  18, 19, 62, I-l, I-9, II-11, and II-17). Immunoglob- 
ulin production in the clones was assayed by RIA and by the hemolytic plaque assay. 
The clones producing the most Ig produced direct plaques, the diameter and clarity 
of which correlated with the amount of IgM detected by the RIA. The clones derived 
from well 19 (IgG2a) and the clones producing lower amounts of IgM antibody (from 
wells II-11, 3, and I-l) gave hemolytic plaques only in the presence of an enhancing 
serum.  The  four clones  secreting  the  highest  amounts of IgM  have  been  kept  in 
continuous passage and have been stable for >9 mo, in terms of growth characteristics 
and immunoglobulin-secretion rates. 
The experiments reported in this paper were performed on the anti-FLU secreting 
clone which was derived from well II-17  and  has been  designated FluIgM-1. This 
clone consistently produced high levels of anti-FLU activity, when tested by RIA or 
the  biosynthetic-labeling technique  described  below.  FluIgM-1  also  produced  the 
largest  direct  anti-FLU  plaques.  These  were  smaller  than  antibody-forming cell 
plaques derived from normal spleen cells, but showed greater homogeneity in size. 
The Presence of Surface Ig on FlulgM-1.  To investigate whether FluIgM-1 expressed 
surface immunoglobulin, FluIgM-1  and the parental NS-1  cells (which produce no 
immunoglobulin)  were  treated  with  rhodamine-labeled  anti-Ig.  The  binding  was 
studied  by  fluorescence  microscopy  and  with  the  FACS.  Significant  binding  of 
rhodamine-labeled anti-Ig to FluIgM-1 compared with NS-1 cells was observed using ANDREW W.  BOYD AND JOHN W.  SCHRADER  1441 
both techniques. FACS fluorescence profiles demonstrating the difference between the 
binding rhodamine-labeled, anti-mouse-Ig-treated FlulgM- 1 and NS- 1 ceils are shown 
in  Fig.  2 A.  Similar experiments showed  that  the  amount  of rhodamine-labeled  Ig 
bound to FlulgM-1  was considerably less than that binding to normal B  cells (data 
not shown). Surface immunoglobulin was also demonstrated by incubating FlulgM- 
1 and NS-1  cells with the anti-FlulgM-I  antiserum,  then staining with  rhodamine- 
conjugated sheep anti-rabbit  antibody, the fluorescence of the FlulgM-1  cells being 
strongly positive, whereas NS-1 cells were negative (Fig. 2 B). 
We also investigated the ability of FlulgM-I  to specifically bind the hapten FLU. 
FlulgM-1  cells  were  incubated  at  37°C  with  FLU-conjugated  proteins  and  after 
washing were analyzed by fluorescence microscopy or by the FACS. NS-1 was again 
used as a  control cell. FluIgM-1  bound FLU20-GEL to a  significantly greater extent 
than did NS- 1. In other experiments, it was shown that this binding was not inhibited 
by unconjugated  GEL. Thus, in that  FlulgM-1  secreted readily detectable amounts 
of IgM  anti-FLU  antibody,  bound  fluorescein  conjugates,  and  had  Ig on  the  cell 
surface, it appeared to be a  suitable cell line  for the study of the antigen-mediated 
blockade of antibody secretion. 
Antigen-mediated Blockade of Hemolytic Plaque Formation.  Initial experiments using the 
hemolytic plaque assay, demonstrated that FluIgM-1  was susceptible to effector-cell 
blockade. FluIgM-1  cells were incubated with  10-50/tg/ml of FLU20GEL for 1 h  at 
37°C.  FLU2oGEL-pretreated  cells  and  control  cells  were  then  washed  twice  and 
assayed in a FLU-specific hemolytic plaque assay. It can be seen that the pretreatment 
of the hybridoma cells with FLU20GEL resulted in a  reduction in plaque numbers of 
~30%, with  a  similar decrease in diameter  (Table I). At  lower doses, where plaque 
numbers were not greatly reduced, plaque size was nevertheless consistently reduced. 
Control  experiments  showed  that  preincubation  of  FluIgM-1  cells  with  either 
FI~. 2.  The presence  of surface immunoglobulin  on FlulgM-1, detected by anti-immunoglobulin 
antisera. (A) FlulgM-I ceils and NS-1 cells were labeled with rhodamine-conjugated sheep anti- 
mouse Ig antiserum. The photograph is a FACS analysis of fluorescence on the vertical axis against 
cell number on the horizontal axis. The left hand peak is the profile generated for NS-1, the right 
hand peak is that for FlulgM-l. (B) NS-I and FlulgM-I cells were labeled with rabbit anti-IgM 
antibody, washed, and then rhodamine-conjugated  sheep anti-rabbit Ig antiserum was added. The 
right hand  curve is the  FlulgM-I  fluorescence profile. The  left hand  curve is  the  NS-I  cells 
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TABLE  I 
The Effect of Preincubation with FLUzoGEL on Hemolytic Plaque Formation by FluIgM-1 
Pretreatment*  Anti-FLU PFC:~ 
~oo +  7§ 
FLU20GEL  10/~g/ml  82 ±  4 
FLU~oGEL  25 p.g/ml  81  +  5 
FLU20GEL  50/Lg/ml  74 +  3§ 
NIPs3GEL 50 #g/ml  93 ±  8 
* Cells  were incubated for 1 h at 37°C with the indicated amounts of FLU20GEL  or NIP33GEL  and then 
washed twice and resuspended in Hepes-buffered Eagle's medium-FCS. 
:~ Plaque assays were performed as described above, counted on a colony microscope, and normalized. 
§ P<  0.02. 
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Fie.  3.  The suppression of secretion and synthesis of IgM in  FluIgM-1, after pretreatment with 
FLU20GEL.  Cells were incubated for 1 h at 37°C with varying amounts of FLU20GEL,  then washed 
and  transferred to  medium  that  contained  tritiated  leucine.  After 4  h  of incubation  they  were 
analyzed in FLU10BSA-coated  microtiter trays. Incorporation of tritiated  leucine is plotted against 
amount of antigen use to pretreat the cells for supernates ([~) and cell  lysates (C)). 
unconjugated  GEL, or GEL conjugated  with  the  unrelated  hapten  mononitroiodo- 
phenyl  (NIP), had  no such  inhibitory effect. These experiments thus  demonstrated 
that the hybrodoma FluIgM-1 was susceptible to effector-cell blockade. 
The Effect of FLU Conjugates on Ig Synthesis.  The chief advantage of using a cloned 
cell line as a  model for the study of ECB is that direct measurements of biosynthesis 
can be made on a homogeneous population of cells. A first approach was to quantitate 
the changes in Ig secretion in ECB and to investigate whether the synthesis of Ig was 
also affected. In these experiments, FluIgM-1 cells were pretreated for 1 h  with FLU 
conjugate, washed twice, then transferred to medium that contained tritiated leucine. 
The cells were allowed to incorporate tritiated leucine for 4 h, after which, cell lysates 
and supernates were assayed for radiolabeled antibody. 
Fig.  3 shows the results of an experiment in which FluIgM-1 cells were pretreated 
with varying amounts of FLUz0GEL. It can be seen that the amount of newly secreted 
antibody was substantially reduced after treatment with amounts of FLUz0-GEL >2 
/~g/ml.  Furthermore,  the  content  of newly  synthesized  Ig  in  cell  lysates  was  also 
reduced in FLU20GEL-pretreated cells. Taken together, these results clearly indicate ANDREW  W.  BOYD  AND JOHN  W.  SCHRADER  1443 
that  pretreatment  of the  hybridoma with  FLU20GEL  markedly  reduced  total  Ig 
synthesis. 
The possibility that the observed reduction in Ig synthesis was an artifact, resulting 
from the persistence of FLU20GEL or its digestion products, was excluded in three 
ways. First, the results obtained using FLUloBSA-coated microtiter tray system were 
checked by mixing varying ratios of control supernates with supernates from cells 
pretreated with FLU20GEL. The supernates had been treated with collagenase in the 
normal way. The results of such an experiment are shown in Table II. It can be seen 
that results are consistent with those predicted by the assumption of simple mixing of 
the  control  and  treated  supernates.  Thus  there  was  no  evidence that  the  treated 
supernates  contained  material  capable  of interfering  with  binding  of anti-FLU 
antibody to the FLUxoBSA plates. 
In a second approach, assays of biosynthetically labeled supernates were performed 
in trays coated with anti-#-chain antiserum. As shown in Table III, the results of 
assays using anti-#-chain-antibody-coated trays were  in  good  agreement  with  the 
results obtained with antigen-coated trays (although the sensitivity and background 
counts of the two systems differed).  Finally, a  different approach  was to  measure 
TABLE  II 
The Effect on the Anti-FLU Antibody Assay of Mixing Supernates  from Control and Pretreated Cultures 
[aH]Leucine 
Control 
Pretreated* 
Pretreated (25%) +  control (75%):~ 
Pretreated (50%) +  control (59%) 
Pretreated (75%) +  control (25%) 
cpm/ lO  6 cells 
15,235  ±  1,094 
7,357  +  821 
12,931  ±  40 
10,532  ±  215 
8,264 ±  72 
* Cells were pretreated with 25 #g/ml of FLU20GEL for 1 h at 37*C. 
:]: Mixtures of supernates from cultures pretreated with FLUz0GEL and control cultures were prepared in 
the proportions shown, and aliquots assayed with control and pretreated supernates. 
TABLE III 
Comparison of Assays of FlulgM-1 Antibody Using P VC Plates Coated with Anti-p-Chain  Antibody or 
FLUto BSA 
Experiment  Pretreatment 
number 
Counts per minute of [aH]leucine-labeled 
FiuIgM-1 bound to trays coated 
with 
Anti-#-chain antibody  FLUlo BSA 
--  2,504 :l: 76  5,400 ±  161 
FLU2oGEL 5/xg/ml  1,685 ±  45*  2,624 ±  33:1: 
FLU~oGEL 10 #g]ml  1,482 :t: 39*  2,138 ±  575 
--  5,963 ±  219  22,147 ±  874 
FLU2oGEL 5 #g/ml  4,834 ±  177'  11,157  ±  644:1: 
FLUaoGEL 10 pg/ml  4,499 ±  135"  8,803 ±  471:]: 
Cells  were  pretreated  with  FLU~oGEL  for  1  h  at  370C  as  shown  above,  then  washed  twice,  and 
biosynthetically labeled for 4  h. Aliquots were assayed in microtiter plates labeled with either anti-/z- 
chain antiserum, or with FLU~oBSA. Two experiments are shown above. 
* 0.001  <  P <  0.01  compared to controls. 
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biosynthetically labeled  antibody  by using  anti-/t-chain  antiserum  and  protein  A- 
bearing staphylocci to precipitate IgM (Table V). 
The close parallels between the results obtained with these methods again indicates 
that any residual  FLU20GEL or the digestion products of the collagenase treatment 
were not interfering with binding to FLUz0BSA-coated plates. 
Specificity  of Blockade  of Ig  Synthesis  Using  Other  Haptens.  In  these  experiments, 
NIP33GEL and  DNP33GEL were  used  to  pretreat  hybridoma cells  and  the  results 
compared with identically prepared control and FLUz0GEL-treated cells.  The results 
(Tables IV and V) show that only the FLU20GEL produced blockade and thus that 
the effect was hapten specific and not related to the carrier protein. 
The Effect of Carrier and Conjugation Ratio on Blockade.  These experiments investigated 
the effects of varying the conjugation ratio in conjugates of FLU with BSA, human 
gamma globulin (HGG), and GEL (Table V). As specific digestion of carrier protein 
was not possible for BSA and HGG, it was necessary to measure antibody levels  with 
a  method  that  was  not  interfered  with  by persisting  antigen.  Therefore  anti-FLU 
antibody levels  were  determined  by indirect  coprecipitation  using  an  anti-/t-chain 
antiserum and staphylococci. 
The results obtained show that blockade was much more readily induced by the 
highly substituted conjugates. A comparison of 50/tg/ml of FLUsHGG with  10/tg/ 
ml of FLU24HGG illustrates this point. The total molarity of FLU is nearly identical 
in both groups but clearly the highly substituted  conjugate is far more suppressive. 
Furthermore, it  was evident that HGG conjugates were more suppressive than  BSA 
or GEL conjugates. The larger size of HGG and the flexible nature of this molecule 
might facilitate interaction with multiple Ig receptors.  Taken with  the requirement 
for multivalency, these data suggest that multipoint binding to surface receptors may 
be an important step in ECB of Ig synthesis. 
Effect of Pretreatment with FLUz,  o-GEL on  Total Cell Protein Synthesis.  To investigate 
whether  the  observed  reduction  in  Ig synthesis  in  blockaded  cells  was  specific,  or 
reflected  rather  a  general  suppression  of protein  synthesis;  total  TCA precipitable 
counts were compared with  those present  in  immunoprecipitates  or in  the  FLU10- 
BSA-coated wells. 
In Fig.  4 the results  of two experiments  are  tabulated  as a  percentage of control 
counts. The TCA-precipitable counts in the supernates were reduced in FLU20GEL- 
treated cultures.  This is understandable as  Ig forms a  major component of proteins 
released  into  the  supernate  by  this  cell  line  (A.  W.  Boyd.  Unpublished  data.). 
TABLE  IV 
The Effect of Specificity of Antigen on Blockade of lg Secretion 
Pretreatment  [SH]Leucine 
cpm/lO  6 cells" 
--  12,673 + 516 
FLU~0GEL 50 p,g/ml  3,350 4- 125" 
NIPsaGEL 50/.tg/rnl  13,052 4- 285 
DNPasGEL 50 pg/ml  11,676 4- 460 
FluIgM-1 cells were incubated with the antigen for 1 h at 37°C, washed twice, then biosynthetically 
labeled. Supernates were assayed in FLUl0BSA-coated  microtiter trays. 
* P < 0.001 for control versus FLU~0GEL  treated; control versus NIP33GEL or DNP33GEL treated: P > 
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TABLE  V 
The Effect of Multivalency and the Nature of the Carrier on the Induction of ECB m FlulgM-I Cells 
Pretreatment  Supernate  Cell lysate 
FlulgM- 1  --  4,688 ± 97  2,099 ± 87 
NIPaoGEL (10/xg]ml)  4,373 ± 66  2,045 ±  74 
NIPaaGEL (50 #g/ml)  4,852  ± 43  2,328 + 81 
FLUs.TGEL (10 #g/ml)  4,510 ±  144  1,980 ± 31 
FLUa.~GEL  (50 p.g/ml)  4,104 + 97  2,228 4- 81 
FLU~GEL (10/~g/mi)  934 ± 44*  1,211 ± 56* 
FLUz0GEL (50 ~g/ml)  832 ±  13"  1,046 ±  74* 
FLUzBSA (10/~g/ml)  3,879 4- 200*  2,121 4- 96 
FLU3BSA (50 p.g/ml)  2,528 4- 58*  2,498 4- 28 
FLUIIBSA (10/xg/ml)  1,209 ±  73*  1,251 ± 40* 
FLUnBSA (50 #g/ml)  795 4- 56*  939 4- 29* 
FLUsHGG (10/tg/ml)  4,435 ±  155  2,073 ± 87 
FLUsHGG (50 #g/ml)  2,998 ±  150"  1,631 4- 71:]: 
FLUlxHGG (10/tg/ml)  832 4- 10"  2,047 4- 38 
FLU~1HGG (50 ~g/ml)  671 4- 18"  1,857 4- 17:~ 
FLU24HGG (10/tg/ml)  934 ± 44*  1,211 ± 56* 
FLUa~HGG (50/~g/ml)  832 ±  13"  1,046 ±  74* 
NS-1  253 ± 30  703 ± 29 
Cells were blockaded with FLU conjugates as shown, with the substitutions indicated by subscript in 
each case. The supernates and cell lysates  were analyzed by staphylococcal immunoprecipitation using 
anti-#-chain antiserum. 
* P <  0.001 versus control. 
:]: P <  0.01, other results not significantly different from controls. 
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Fio.  4.  Comparison of immunoglobulin specific  and total protein  [aH]leucine incorporation in 
control  and  FLUa0GEL-pretreated  FluIgM-I  cells.  Two  experiments  are  shown  that  compare 
incorporation of tritiated leucine  into supernates and  cell  lysates by  three methods:  (~)  TCA 
precipitation, ([-[) immunoprecipitation (direct coprecipitation with FLUIoBSA),  (t'~) FLUI0BSA- 
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However,  the  cell  lysates  show  no  change  in  TCA-precipitable  counts  relative  to 
controls, despite a significant reduction in Ig-specific counts. Thus blockade seems to 
affect Ig synthesis specifically. 
DATA Synthesis  Rate.  The incorporation  of tritiated  thymidine  by the  hybridoma 
was  measured  at  various  times  after  pretreatment  with  FLU20GEL and  compared 
with that in both control cells and cells continuously exposed to FLU20GEL. At each 
time point, thymidine was added and incorporation over the next 4 h  was measured. 
As is seen in Table VI, no significant  differences were observed between  these three 
groups. Further, the cell numbers in all three groups at 24 and 48 h were never >10% 
different,  with  no significant  trend  in  either  direction  detectable  over a  number of 
experiments.  Thus  the  mechanism  of blockade  does  not  appear  to  involve  either 
accelerated cell death or a change in numbers of dividing cells. 
Recovery from Blockade.  The duration  of the blockade of Ig synthesis that  followed 
pretreatment of the hybridoma cells with antigen was investigated by pretreating cells 
with  10  /tg/ml  of FLU20GEL  for  1  h,  washing  them  and  resuspending  them  for 
varying periods  in  DME-FCS  at  37°C  in  2-ml  Petri  dishes.  After  varying periods, 
FLU20GEL-pretreated  cells  were  compared  with  control  cells.  At  each  time  point, 
aliquots  of cells  were  washed  and  resuspended  in  [3H]leucine-containing  medium. 
Biosynthetic  labeling  was  carried  out  for 4  h,  after  which,  amounts  of 3H-labeled 
antibody were determined  as before.  The results  are plotted  in  Fig.  5, and  indicate 
that  suppression  is  maximal  between  0-6  h,  but  only slight  at  24  h,  and  by 48  h, 
pretreated  cells  have  recovered  and  synthesize  Ig at  a  rate  comparable  to  that  of 
control cells.  The continuous presence of antigen  in the culture  medium was shown 
to inhibit  this recovery (Fig. 5). 
Fc  Rosette  Assay  on  FluIgM-1  Cells.  One  possibility  not  hitherto  excluded  by 
published  data,  is  that  the  mechanism  of effector-cell  blockade  may involve the  Fc 
receptor. For example Fc receptors could bind secreted antibody that had complexed 
with antigen bound to surface immunoglobulin receptors. To investigate whether the 
hybridoma had Fc receptors, rosetting assays were performed. 
In  the  IgG  rosetting  assay,  peritoneal  exudate  cells  showed  numerous  rosettes 
(>40%)  but FluIgM-1 cells were entirely negative. To investigate the possibility that 
a  FluIgM-1  may have an  Fc receptor specific for/.t chain, rosetting was also carried 
out with erythrocytes coated with mouse IgM anti-SRBC antibodies.  Once again, no 
rosettes  were  observed  (nor  in  this  case  were  they  present  in  assays  of peritoneal 
TABLE  VI 
The Effect of ECB on DNA Synthesis in FluIgM-1  Cells 
Treatment of cells  [3H]Thymidine 
cpm/2 x  105 cells 
4,207 -  397 
Pretreatment for 1 h with FLU20GEL*  4,154 _+ 331 
Continuous presence of FLUzoGEL  (10 #g/ml):~  4,475 --1- 422 
FluIgM-1 cultures were pretreated with I0/tg/ml of FLU20GEL  for 1 h, then washed twice. Incorporation 
was carried out for 4 h. 
* Cells were incubated with [aH]thymidine in medium containing no antigen. 
:~ 10/.tg/ml of FLU20GEL  was added to the medium with the [aH]thymidine. ANDREW W.  BOYD AND JOHN W.  SCHRADER  1447 
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FIG. 5.  Secretion  rate ([3H]leucine incorporation in 4 h) is plotted against time for cells exposed to 
10 #gm/ml of FLU20GEL for 1 h. In one group ([--1),  cells were washed twice and allowed to recover 
(1-h antigen pretreatment). In the second group (O), antigen was present continuously. 
exudate cells performed in parallel). Hence, we may conclude that FluIgM- 1 does not 
have Fc receptors and thus that Fc receptor binding is not a  necessary step in ECB. 
Fluorescence Microscopy of Cells During Antigen Pretreatment.  FluIgM-1  cells  were 
exposed  to  FLU20GEL  at  37°C,  and  aliquots  removed  after  various  times  and 
prepared for fluorescence microscopy. The cells showed a  characteristic sequence of 
changes  (Table VII). By 30 min, fluorescence microscopy showed  that  most of the 
fluorescence was localized in  randomly distributed  bright spots. With  longer times, 
these spots increased in size and decreased in number, but  the general  pattern was 
preserved and capping was never seen. The pattern correlated well with that observed 
in cells treated with rhodamine-conjugated  sheep anti-mouse Ig antiserum,  or with 
other FLU conjugates. 
Fluorescence Microscopy and FACS Analysis of FLUzoGEL-pretreated Cells.  It was  im- 
portant to determine whether the duration of blockade coincided with the persistence 
of antigen in association with the cells. Therefore cells were treated with the blockading 
antigen FLU20GEL at 37°C  for 1 h, washed twice and transferred to fresh medium. 
After varying periods, cells were washed and fixed with paraformaldehyde and stored 
at 4°C until analysis was carried out. 
Cells  fixed immediately after the  pretreatment  periods showed  the characteristic 
pattern of bright fluorescent spots described above. After -4  h  these spots gradually 
reduced in number and intensity, and had virtually disappeared by 24 h. 
Table VIII shows a FACS analysis of pretreated cells, and demonstrates that there 
is a steady decline in the number of fluorescent cells. This result correlated well, both 
with  fluorescent microscopy observations and also with the recovery from blockade 
measured  by biosynthetic  labeling.  Thus  the  blockade of Ig synthesis  in  FluIgM-1 
appears to correlate with the association of antigen  (FLU) with the cell. 
In the light of previous observations that suggested that extracellular antigen was 
critical for the maintenance of ECB, it was of interest to determine how much of the 
FLU20GEL associated with blockaded FluIgM-1  cells was extracellular.  To examine 
this question, cells were treated with collagenase at various times after pretreatment 
with FLU-GEL. The effect of treatment  with collagenase on fluorescence was then 1448  EFFECTOR-CELL  BLOCKADE  IN  A  FLUORESCEIN-SPECIFIC  HYBRIDOMA 
TABLE  VII 
Distribution of Fluorescence on FlulgM-I during the l-h FLU~oGEL Pretreatment, and during the 
Subsequent 23 h  When  No Free Antigen Was Present 
Time  Microscopic appearance of cell-associated antigen 
0* 
5 rain* (a) 
10 min* 
30 min* 
2 h, 
6 h* 
24 h~: 
Only faint, diffuse surface fluorescence. 
Again,  the  diffuse "ring" staining is  evident, but  bright  points of fluorescence are 
beginning to develop. 
Many brightly fluorescent spots, randomly distributed. 
Bright spots are larger, and appear spherical in shape; there are >30/cell. Cytoplasmic 
staining is noted. 
The size of the bright spots continues to increase, but the number is reduced to 20-30/ 
cell. 
There is a continuing reduction in the number of fluorescent spots(10-20/cell). 
Brightness reduced further as a result of continuing decrease in fluorescent spots. 
The cells are much fainter and a  proportion of cells have no visible fluorescence, the 
pattern is still that of a  few (usually less than five)  fluorescent spots. At this stage, 
brightly fluorescent vesicles are seen floating free in the medium. 
The fluorescent microscopic appearance is recorded for hybridoma cells at various times after the addition 
of FLU20GEL (10 p.g/ml) to the cultures. At  1 h, cells were washed twice and then cultured in medium 
that  contained  no  antigen.  At  each  time  point  cells  were  centrifuged  through  FCS  and  fixed  in 
paraformaldehyde, and then prepared for microscopy. 
* Observations during FLU20GEL pretreatment. 
:~ Follow-up observations of blockaded cells. 
TABLE  VIII 
FA CS Analysis of the Fluorescence  of Blockaded FluIgM- 1 Cells 
Time*  Fluorescent cells:~ 
h  % 
0  43.4 
1  56.3 
2  46.9 
6  32.1 
24  6.6 
* FACS analyses of the fluorescence intensity, performed at each time point, of aliquots of cells that had 
been treated with FLU,aoGEL  for 1 h at 37°C and then washed twice. 
$ The fluorescent cells (>channel 20 on the FACS) are expressed as a percentage of a 4 ×  104 cell sample 
for each time point. 
determined  by  fluorescence  microscopy.  At  all  time  points  at  which  fluorescence 
remained  detectable  on  the  cells,  collagenase  treatment  resulted  in  a  significant 
reduction  of FLU  staining.  In particular,  the bright  spots were removed.  The  residual 
fluorescence was mainly  diffuse, although  in some cells there remained  condensations 
of fluorescence  which  appeared  to  be  perinuclear.  This  persistence  of extracellular ANDREW W. BOYD AND JOHN "W. SCHRADER  1449 
antigen during the period when blockade was observed  is consistent with previous 
data on the role of extracellular antigen in mediating blockade. 
Discussion 
The experiments reported in this paper describe a  hybridoma cell line, FluIgM-1, 
which secretes an IgM antibody specific for the hapten FLU. When these cells were 
exposed to highly multivalent FLU conjugates, the secretion rate of antibody was 
suppressed as indicated by hemolytic plaque assays (Table I) and biosynthetic labeling 
(Fig. 3). The rapid onset and dose-response of the phenomenon as seen in FluIgM-1, 
parallelled closely the  ECB  phenomenon  in  normal  spleen  antibody-forming cells 
(AFC) (1-4). 
As  in  normal AFC, the hybridoma cells could only be  blockaded by molecules 
bearing multiple, specific antigenic determinants (Tables IV and V). The data also 
suggest that the nature of the carrier may have been important, as HGG conjugates 
were more suppressive than BSA conjugates of similar hapten substitutions. This may 
reflect the  relatively greater  likelihood of muhipoint  binding by the  larger,  more 
flexible HGG conjugates compared with BSA conjugates. Taken together with the 
observation that FLU conjugates capable of inducing blockade form surface aggre- 
gates (Table VII), this suggests that cross-linking of Ig receptors may be an important 
factor in inducing and maintaining blockade. 
Several observations were pertinent to the role of antigen aggregates in the ECB 
phenomenon. Parallel measurement of Ig secretion rate, with direct observation of 
the cell-associated fluorescent aggregates, showed that the clearance of antigen from 
the cells correlated with recovery of Ig secretion rates. Furthermore, at all times when 
cell-associated  antigen  remained  detectable,  at  least  a  portion  was  accessible  to 
enzymatic digestion. This was in accord with previous observation on normal spleen 
AFC (2), indicating that surface bound antigen was necessary to induce and maintain 
ECB. 
One possibility not hitherto excluded was that Fc receptors, which appear to be 
involved in other examples of B cell down regulation (18),  may be involved in the 
mechanism of ECB. The demonstration that ECB can be induced by nonimmuno- 
globulin antigens  (e.g.,  FLU20GEL, FLUnBSA) does not exclude a  role for the Fc 
receptor. Secreted antibody could bind to any type of muhivalent antigen bound to 
the cell surface, forming a  local antibody-antigen complex, and the Fc pieces of the 
secreted antibody in this complex could bind to Fc receptor on the cell. This study 
excludes a critical role for the Fc receptor in ECB however, as FluIgM-1 was shown 
to lack receptors for IgG or IgM isotypes. Thus Ig receptor may be the sole inducing 
signal for ECB. 
In  conclusion,  induction  of ECB  in  the  hybridoma cell  line  described,  closely 
parallels that in IgM-secreting splenic AFC. This hybridoma furthermore, offers the 
unique advantage of allowing direct visualization of the specific antigen (FLU), and 
as it is a  homogeneous cell population, facilitates the investigation of the molecular 
events resulting in suppression of Ig synthesis. Finally, further study of the mechanism 
of ECB in this hybridoma may shed light on other phenomena in which Ig-receptor 
binding is important, such as B cell proliferation and tolerance induction. 1450  EFFECTOR-CELL  BLOCKADE IN A FLUORESCEIN-SPECIFIC  HYBRIDOMA 
Summary 
A mouse hybridoma cell line, FluIgM-1, which secretes IgM specific for the hapten 
fluorescein (FLU) was developed to allow detailed analysis of the effector-cell blockade 
(ECB) phenomenon, in which contact of antibody-forming cells (AFC) with specific 
antigen results in marked reduction of antibody secretion. 
Treatment  of  hybridoma  cells  with  highly  substituted  FLU  conjugates  (e.g., 
FLUz0gelatin)  resulted  in  inhibition  of plaque  formation. The data  indicated  close 
parallels with the ECB of normal spleen AFC, both in speed of onset and the dose of 
antigen required. The inhibition of antibody secretion was confirmed with a  biosyn- 
thetic-labeling procedure which  demonstrated  that  this  was  a  result  of reduced  Ig 
synthesis. The inhibitory effect appeared to be confined to antibody synthesis, in that 
total protein synthesis, DNA synthesis, and cell-doubling times were unaffected. 
The association of FLU conjugates with  the cells  during and  following ECB was 
studied  directly  using  fluorescence  microscopy and  the  fluorescence-activated  cell 
sorter. These experiments showed that FLU conjugates capable of causing blockade 
aggregated on the cell surface, that the clearance of cell-associated antigen correlated 
with  recovery from  ECB,  and  that  at  all  times  when  cell  associated  antigen  was 
detectable,  a  portion  remained  bound  to  the  cell  surface  and  was  susceptible  to 
enzymatic removal. The  latter  observations supported  previous  findings suggesting 
that ECB was mediated by extracellular antigen. The direct observation of aggregates 
of antigen on the surface of blockaded cells  is consistent with a mechanism involving 
cross-linking of Ig receptors. Finally, Fc receptors were not present on hybridoma cells, 
excluding their involvement in induction of ECB. 
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